Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

Cancer

Volumn 95, Issue 4, 2002, Pages 751-757

  Bellmunt, Joaquim ^a   Albanell, Joan ^a   Paz Ares, Luis ^b   Climent, Miguel A ^c   González Larriba, Jose L ^d   Carles, Joan ^e   De La Cruz, Juan J ^f   Guillem, Vicente ^c   Díaz Rubio, Eduardo ^d   Cortés Funes, Hernan ^b   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Advanced urothelial tumors; Chemotherapy; Cisplatin; Gemcitabine; Paclitaxel; Prognostic factors; Transitional cell carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 0037103074     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10762     Document Type: Article

References (27)

1. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium
2. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study
3. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience
4. Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world
5. Long term follow-up of a Phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
6. Prognostic factor for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
7. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
8. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
9. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
10. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A Phase II trial of the Eastern Cooperative Oncology Group
11. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study
12. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer
13. Phase II study of paclitaxel and cisplatin in advanced urothelial carcinoma
14. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
15. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A Phase II trial of the National Cancer Institute of Canada Clinical Trials Group
16. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A Phase II clinical trial
17. Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: Preliminary results
18. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
19. Phase I/II trial of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma
20. A Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium
21. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study
22. The role of taxanes in the management of breast cancer
23. Nonparametric estimation from incomplete observations
24. Docetaxel and cisplatin in metastatic urothelial cancer: A Phase II study
25. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A Phase II trial
26. Phase I/II study of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma: A well tolerated regimen with activity independent of p53 mutation
27. Evaluating mdm-2 and p53 in muscle-invasive node-negative transitional cell carcinoma (TCC) of the bladder treated with cisplatin-based neo-adjuvant chemotherapy